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Summary
Purpose: To retrospectively review our experience with VNS in pediatric patients with
pharmacoresistant epilepsy and examine the seizure-frequency outcome and rates of
discontinuation in two age groups: adolescent and pre-adolescent children.
Results: Complete pre- and post-VNS data were available for 46/49 patients. Median
age at implantation was 12.1 (range 2.3—17.9) and median duration of epilepsy 8.0
(1.9—16.9) years. Twenty-one patients (45.6%) were under 12 years at the time of
surgery. Median follow-up was 2 years; follow-up exceeded 4 years in 9/46 patients.
As compared to baseline, median seizure-frequency reduction in the setting of
declining numbers was 56% at 3 months, 50% at 6, 63% at 12, 83% at 24 and 74% at 36
months. When a last observation carried forward analysis was employed median
seizure-frequency reduction in the range of 60% was observed at 1, 2 and 3 years post-
VNS. Twenty patients (43.5%) had >75% seizure-frequency reduction. No response
(increase or <50% reduction) was observed in 19/46 (41.3%). Five patients (10.1%)
were seizure-free for more than 6 months by their last follow-up. There was no
difference in the number of AEDs used before and after VNS. The long-term dis-
continuation rate was 21.7% and reflected a lack of clinical response or infection.
Conclusions: In this series VNS was well-tolerated and effective as add-on therapy for
refractory seizures in children of all ages. Response was even more favorable in the
younger group (<12 years at implantation). Infection and lack of efficacy were the
most common reasons for discontinuation of long-term VNS therapy in this group.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +1 216 444 3629; fax: +1 216 445 4378.
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492 A.V. Alexopoulos et al.Introduction
Vagus nerve stimulation (VNS) was introduced in the
U.S. in 1997 as adjunctive therapy ‘‘in adults and
adolescents over 12 years of age with partial onset
seizures, which are refractory to antiepileptic med-
ications’’. Left cervical VNS remains the only form of
chronic, intermittent neuroelectrical brain stimula-
tion that has shown efficacy and safety in patients
with epilepsy based on prospective, randomized
controlled studies.1,2
The device offers a non-pharmacologic therapeu-
tic alternative for patients with pharmacoresistant
epilepsy. Several articles have reported benefit of
VNS in children presenting with a variety of epilepsy
syndromes.3—5 During the pre-approval phase the
manufacturer of the VNS therapy system (Cybero-
nics Inc., Houston, TX) sponsored two randomized,
double blind, active-control trials (E03 and E05) that
compared two different VNS stimulation protocols
for the treatment of focal seizures in patients older
than 12 years of age: high ‘‘therapeutic’’ stimulation
and low ‘‘control’’ stimulation. Because no formal
clinical trials have been carried out in pre-adoles-
cent children (children who are less than 12 years
old at the time of VNS implantation) the FDA has not
approved the use of the device in this age group.
The two pre-approval studies had a 12-week
prospective baseline assessment period, a 2-week
recovery period post-VNS insertion and a 12—16
week active treatment period. Both trials had con-
cealed randomization, blinded assessment and ade-
quate follow-up data. However, the 3—4 months of
blinded follow-up post-implantation is a rather lim-
ited period of observation, if one were to consider
the paroxysmal nature of epilepsy. Consequently,
the long-term effect of vagus nerve stimulators
remains to be determined empirically or in uncon-
trolled studies.
An abundance of uncontrolled long-term follow-
up data is available in adults. More than 50% seizure
reduction was observed in 39% of patients after 15
months of high ‘‘therapeutic’’ stimulation during
the open-label, non-blinded extension of E05 (XE5
trial).6 In the open-label study by Morris and Mueller
a total of 440 patients were followed for up to 3
years; more than 50% seizure reduction was
observed in 43% of patients at 3 years post-implan-
tation.7 Similar improvements have been reported
up to five8 or more years of chronic VNS.9
It should be emphasized that only 19 adolescents
(patients between 12 and 18 years) were included in
the two double-blind pre-approval studies.10 Open-
label add-on clinical data on VNS use in children
featuring various epilepsy syndromes and follow-up
durations have been reported since. To this dayfewer publications address the effectiveness and
safety of the device in children as compared to
adults.11 This retrospective study contributes to
the long-term experience of chronic VNS use in
adolescent and preadolescent children.
The objectives of the study were to determine
the long-term efficacy of VNS in children with phar-
macoresistant epilepsy referred to a tertiary epi-
lepsy center, to compare the efficacy in two age
groups pre-adolescent children <12 years of age at
the time of VNS implantation versus adolescent
children >12 years of age, and to evaluate the
reasons families elect to discontinue chronic VNS.Materials and methods
A list of patients, who underwent VNS implantation
at our center, was obtained from operating room
records. The study was approved by the Institutional
Review Board (IRB# 5701). Children and adolescents
of all ages with pharmacoresistant focal or general-
ized epilepsy were included. The VNS therapy sys-
tem was implanted by the same neurosurgeon
(W.E.B.) and was programmed in the operating room
in all cases.
Stimulation parameters were adjusted in line with
standard medical practice for VNS implanted
patients.12 Initial stimulation parameters were (out-
put current = 0.25 mA, frequency = 30 Hz, pulse
width = 250 ms, signal on-time = 30 s and off-
time = 5 min).Visits for interrogationandadjustment
of the device occurred at least every 1—3 months for
the first 3—6 months and every 6—12 months there-
after. The stimulus intensity was increased stepwise
by 0.25 mA until 1 mA. Next, the off-time was shor-
tened. Adjustments to signal frequency and rapid
cycling were not performed routinely. The maximum
currentused inourpatientswas2.5 mA.Antiepileptic
drugs (AEDs)were typically left unchangedduring the
first 12months unless adjustmentswere necessitated
by increasing seizures or drug toxicity.
Variables included age at onset of epilepsy and at
the time of VNS implantation, duration of epilepsy,
seizure types and presumed cause(s), presence or
absence of developmental disabilities and/or other
related medical conditions, presence or absence of
MRI abnormalities and results of comprehensive
epilepsy evaluations. Patients’ demographic and
clinical characteristics divided in two groups based
on their age at the time of VNS implantation are
presented in Tables 1 (pre-adolescent children <12
years) and 2 (older children>12 years of age at time
of VNS surgery).
All patients had at least one baseline assessment
within 4—8 weeks before surgery and were followed
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Table 1 Demographics and clinical characteristics of all children younger than 12 years at the time of VNS implantation (n = 21)
No. Sex Age at
VNS
Age of
onset
(years)
Epilepsy
syndrome
Etiology Seizure
semiology
Related
medical
conditions
MRI Duration of
follow-up
Seizure-
frequency
1 F 3.6 3 months Focal (Midline) Cryptogenic GTC Developmental
delay Thoracic
Dermoid
Normal
(preop)
60 Seizure-free
2 M 10.9 4 months Generalized Cryptogenic GTC &
CPS
Developmental
delay ADHD
Normal 12 >75%
3 F 4.2 2 months Multifocal
(B/L Independent)
Cryptogenic CPS Severe
developmental
delay
Normal 48 >90%
4 M 9.9 3 months Generalized Symptomatic
(MCD)
GTC &
Absence
Severe
developmental
delay
Lissencephaly 12 <50%
5 F 2.3 2.5 months Multifocal Cryptogenic GTC &
Myoclonic
Developmental
delay
Slight white
matter
maturation
delay for age
6 Increase
6 M 9.5 3 months Generalized Symptomatic (TS) Myoclonic &
Absence
Severe
developmental
delay
Bilateral
subependymal
nodules
24 >50%
7 M 10.4 4 months Generalized Cryptogenic Drop
Attacks &
GTC
Severe
developmental
delay
Spastic
quadriparesis
Mild diffuse
thinning of
corpus callosum
48 >90%
8 M 8.6 10 months Generalized Symptomatic (TS) Spasms Developmental
delay
Multiple
bilateral tubers
48 Seizure-free
9 F 7.3 9 months Focal
(Left parieto-
occipital)
Cryptogenic 28GTC &
CPS
Severe
developmental
delay Arnold
Chiari type II
Normal (preop) 48 >75%
10 M 10.1 3 years Focal Hypothalamic
hamartoma
28GTC &
Absence
Mild
developmental
delay ADHD
Hypothalamic
hamartoma
36 >75%*
11 F 8.2 9 months Generalized Cryptogenic GTC &
Myoclonic
Developmental
delay
Normal 36 >90%
12 F 3.9 1 year Generalized Cryptogenic Myoclonic Developmental
delay
Normal 48 Seizure-free
13 M 5.5 1.7 year Generalized Cryptogenic Atonic
& Absence
Developmental
delay
Behavioral
dyscontrol
Normal 36 >90%
14 M 11 5 years Generalized
(Childhood
absence)
Idiopathic Absence Asperger’s
syndrome ADHD
Normal 24 Seizure-free
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Table 1 (Continued )
No. Sex Age at
VNS
Age of
onset
(years)
Epilepsy
syndrome
Etiology Seizure
semiology
Related
medical
conditions
MRI Duration of
follow-up
Seizure-
frequency
15 M 5.4 1.5 years Generalized Cryptogenic Absence None Dysmorphic
bilateral
hippocampal
formations
24 >75%
16 M 8.2 6.2 years Generalized Symptomatic
(MCD)
Atonic
& Absence
Developmental
delay
Language
disorder
Bilateral
perisylvian
macrogyria
12 Seizure-free
17 F 6 1.2 years Generalized Cryptogenic GTC
& Absence
Developmental
delay ADHD
Normal 12 >50%
18 F 8 6 months Multifocal Symptomatic
(Rett syndrome)
Drop Attacks
& Myoclonic
Severe
developmental
delay
Precocious
puberty
Bilateral MCDs
(Frontal
lobe & insula)
12 >50%
19 F 10.7 8.7 years Generalized Cryptogenic CPS! 28GTC PDD/Autism Mild diffuse
atrophy
12 <50%
20 M 6.1 11 months Multifocal Symptomatic
(MCD)
Myoclonic
clusters
Developmental
delay
Goldenhar
syndrome
Septo-opto
dysplasia
Ventriculomegaly
6 <50%
21 F 6.5 3.5 months Generalized Genetic
(Mitochondrial)
Spasms Developmental
delay
Generalized
parenchymal
atrophy
6 <50%
Twenty-one pre-adolescent children treated with VNS between 1997 and 2003 (the last column refers to seizure-frequency change at last follow-up). Abbreviations: ADHD, attention deficit hyperactivity disorder; AED, antiepileptic
drug; B/L, bilateral; CPS, complex partial seizure; GTC, generalized tonic—clonic; Lt, left; MC, myoclonic; MCD, malformation of cortical development; MELAS, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like
episodes; PDD, pervasive developmental disorder; Rt, right; SE, status epilepticus; TS, tuberous sclerosis; 28GTC, secondarily generalized tonic—clonic. Asterisk (*) denotes children who died during the period of observation following
VNS implantation.
Patient 1: Failed two previous resective surgeries of the left posterior quadrant at outside institution. Has history of recurrent bouts of status epilepticus.
Patient 3: Developed post-operative wound infection, and treated successfully with intravenous antibiotics. VNS battery replaced 33 months after initial implantation.
Patient 4: Device turned off at 12 months due to lack of appreciable benefit. (Can still be activated on-demand by swiping the magnet).
Patient 5: Device removed 20 months post-implantation because of lack of clinical benefit.
Patient 6: VNS battery replaced 29 months after initial implantation. Following battery change patient developed purulent post-operative wound infection and had device explanted 20 days later. The device has not been replaced.
Patient 8: New seizure type (nocturnal GTC seizures) emerged 24 months after VNS implantation; they were eliminated within 3 months after increasing AED doses.
Patient 9: Failed previous cortical resection of the left posterior quadrant. Has history of protracted seizures/status epilepticus associated with prolonged periods of apnea.
Patient 10: Developed obstructive hydrocephalus, treated with transcallosal third ventriculostomy. Patient died approximately 1 month after surgery (*).
Patient 13: End of battery service and replacement of old with new generator 3.5 years after initial VNS implantation.
Patient 15: Experienced unintended activations because he insisted to wear the magnet on his left wrist.
Patient 16: Has been complaining of mild chronic chest pain localized at the bottom of the generator site (no objective findings on exam).
Patient 20: Developed soft tissue, non-tender, and fluctuant swelling over the generator site associated with low-grade fever 5 months after insertion, device explanted at 6 months.
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Table 2 Demographics and clinical characteristics of all children older than 12 years at the time of VNS implantation (n = 25)
No. Sex Age at
VNS
Age of
onset
Epilepsy
Classification
Etiology Seizure
semiology
Related medical
conditions
MRI Duration of
follow-up
Seizure-
frequency
1 F 13.3 6 years Multifocal
(B/L Independent)
Symptomatic
(Encephalitis)
CPS Behavioral
dyscontrol
Normal 60 >75%*
2 F 13.5 3 years Right Hemisphere Cryptogenic GTC & CPS Rubinstein-Taybi Mild diffuse atrophy 36 <50%
3 M 12.1 5 months Multifocal
(B/L Independent)
Cryptogenic GTC Mild develop.
delay
Subtle, diffuse
sulcation abnormality
6 <50%
4 M 14.5 9 years Multifocal Genetic
(Mitochondrial)
GTC & CPS ADHD Progressive atrophy
w/ multiple infarcts
12 <50%
5 M 13.2 1.5 years Generalized Cryptogenic Drop Attacks
& GTC
Severe develop.
delay
Normal 48 >50%*
6 F 14.4 3 years Generalized
and Right Focal
Cryptogenic GTC & Absence ADHD
Hypersomnolence
Normal 24 >90%
7 M 17.4 7 years Focal (Left
parieto-occipital)
Cryptogenic CPS None Dysmorphic left
hippocampal formation
6 Increase
8 M 17.25 4 months Childhood absence Idiopathic GTC &
Absence
ADHD Normal 36 <50%
9 F 17.4 8.5 years Juvenile myoclonic
epilepsy
Idiopathic Absence
(rare GTC)
Hypothyroidism
Non-epileptic
seizures
Normal 48 >90%
10 F 14.1 2 years Generalized Symptomatic
(Head Trauma)
CPS! 28GTC Developmental
delay
Bifrontal
encephalomalacia
36 >90%
11 M 12.5 2.5 years Generalized Symptomatic
(MCD)
Atonic
& GTC
Developmental
delay
Bihemispheric nearly
transcortical MCDs
24 >75%
12 F 12.2 3 years Generalized
(Doose Syndrome)
Cryptogenic GTC
& Myoclonic
None Normal 3 >75%
13 F 14.7 4 months Generalized Cryptogenic Myoclonic & CPS Severe develop.
delay
Spastic quadriparesis
Dysmorphic left
hippocampal formation
24 >50%
14 M 13.6 1.5 years Multifocal
(B/L independent)
Cryptogenic CPS Developmental delay
Short stature
Normal 12 >50%
15 F 17.9 10 years Generalized Symptomatic
(TS)
GTC
& Myoclonic
Developmental delay Multiple
subependymal nodules
24 >75%
16 M 12 8 years Focal (Left centro-
temporal)
Cryptogenic CPS Depression Behavioral
dyscontrol
Mild diffuse atrophy 12 <50%
17 F 14.1 3 months Generalized Cryptogenic Myoclonic Developmental delay
Cortical blindness
Bilateral sulcation
abnor. (Frontal,
Cingulate)
6 >50%
18 F 12 9 months Multifocal Cryptogenic GTC Pervasive develop.
disorder
Normal 12 Increase
u
p
at
re
gu
lar
in
te
rvals
at
3,
6
an
d
12
m
o
n
th
s
afte
r
496
A
.V.
A
le
xo
p
o
u
lo
s
e
t
al.
Table 2 (Continued )
No. Sex Age at
VNS
Age of
onset
Epilepsy
Classification
Etiology Seizure
semiology
Related medical
conditions
RI Duration of
follow-up
Seizure-
frequency
19 M 14.5 2.5 years Generalized Cryptogenic GTC &
Myoclonic
Developmental
delay ADHD
ormal 12 Increase
20 M 15 4 months Multifocal Cryptogenic 28GTC Severe
develop. delay
SE! Brain hypoxia
ormal 12 <50%
21 M 16.75 2 months Generalized Cryptogenic GTC Developmental delay
Spastic quadriparesis
ormal 12 <50%
22 M 12.1 4 years Generalized Idiopathic MC & Absence Mild speech delay ormal 12 Increase
23 M 16.7 10 years Multifocal
(B/L
independent)
Symptomatic
(Encephalitis)
GTC & CPS Learning disability
Anxiety disorder
ormal 12 Increase
24 M 15.6 3 years Multifocal Symptomatic
(MCD)
28GTC & Rt face
clonic
Oromotor apraxia ilateral
erisylvian
olymicrogyria
36 Increase
25 F 17.8 13.5 Focal
(Lt Temporal)
Cryptogenic CPS None ormal 12 <50%
Twenty-five adolescents treated with VNS between 1997 and 2003 (the last column refers to seizure-frequency at last follow-u . Abbreviations: ADHD, attention deficit hyperactivity
disorder; AED, antiepileptic drug; B/L, bilateral; CPS, complex partial seizure; GTC, generalized tonic—clonic; Lt, left; MC, myoclo c; MCD, malformation of cortical development; MELAS,
mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes; PDD, pervasive developmental disorder; Rt, rig ; SE, status epilepticus; TS, tuberous sclerosis; 28GTC,
secondarily generalized tonic—clonic. Asterisk (*) denotes children who died during the period of observation following VNS imp ntation.
Patient 1: Mild throat pain during stimulation. Patient died of probable SUDEP 6 years after VNS implantation (*).
Patient 2: Excessive drooling and aspiration pneumonia on higher current settings, resolved with lowering of current intensity. T device was turned off 42 months after implantation,
because of lack of clinical benefit.
Patient 5: Patient died of probable SUDEP 4 years post-VNS implantation (*).
Patient 6: VNS battery replaced 48 months after implantation.
Patient 7: Experienced prolonged episodes of seizures and peri-ictal apneas following VNS implantation Device turned off becau of lack of clinical benefit 1 year after implantation.
Patient 8: Patient’s family elected not to replace the generator’s battery at the end of service (40 months after initial implanta on).
Patient 9: Patient became pregnant 3 years after VNS implantation and while receiving a combination of lamotrigine and topiramat Antiepileptic medications were maintained throughout
pregnancy, which resulted in a full-term infant with a non-life-threatening ventricular septal defect.
Patient 12: Developed a post-operative wound infection with partial dehiscence after ‘‘picking’’ at her wound-device was explant 3 months after initial implantation. Generator has not
been replaced, although 2 years later family expressed interest to proceed with replacement.
Patient 17: Initially received VNS implant at 13 years of age, but device explanted 2 weeks later due to wound infection (patient ‘‘p ying with the sutures’’). VNS re-implanted 1 year later.
Patient 21: History of anterior 2/3 corpus callosotomy at 6 years followed by completion of transection 6 months later, which co trolled drop attacks but left GTC seizures unchanged.
Patient 22: Minimal voice change during stimulation. Experienced 2 GTC seizures for first time after starting VNS. Also, habitual myo onic seizures became ‘‘longer and harder’’ according to
parents.
Patient 23: Had VNS device turned off after 1 year (due to lack of benefit). Device was subsequently removed.
Patient 24: Seizure semiology and ictal SPECT indicated a left hemispheric seizure origin. Patient underwent left peri-rolandic sub ral evaluation 3 years after VNS, which did not show a
discrete epileptogenic region. After replacement of depleted VNS battery (40 months) patient has been using the device exclus ely on demand (patient and family state that magnet
activation occasionally decreases seizure duration and severity). Also has history of stimulation-induced throat pain and coughin at current intensities >1.75 mA.
Patient 25: Because of intact verbal memory function on neuropsychological testing family elected VNS implantation. A year later th device was removed because of lack of clinical benefit.M
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were obtained from patients’ regular yearly follow-
up visits (at 2, 3 and 4 years after insertion of the VNS
generator). Data fromyearly follow-up appointments
(at 12, 24, 36 and 48 months) were included, if
patients had been seen within 1—2 months from
the specified follow-up time. VNS data derived from
additional VNS-related assessments (for example at 1
month post-implantation) or during routine neurol-
ogy clinic and/or emergent hospital visits were not
included in the analysis. Minimal follow-up was 6
months post-implantation, except for one patient
who developed a post-operative wound infection
and had the device explanted a few days after her
3-month post-implantation follow-up.
Patient data were collected from standardized
seizure-frequency forms, which were used at each
VNS-related visit. Monthly seizure-frequency data
were obtained from patients, parents and/or care-
givers. In patients with more than one type of
seizures data were collected for overall monthly
seizure-frequencies. This information was entered
into a database and was available for subsequent
analysis.
The following outcome variables were assessed:
(a) percentage change in total seizure-frequency
during treatment relative to baseline, (b) seizure
responder rate, i.e. percentage of patients who had
at least 50% reduction in total seizure-frequency
during treatment, and (c) treatment withdrawal
(any reason).
Post-implantation seizure-frequency change in a
non-fixed pediatric population was examined in two
ways, as previously reported by Morris and Mueller7
In the setting of declining numbers during extended
periods of follow-up one type of analysis includes
only data available for the corresponding time per-
iods (declining numbers analysis). The second
approach by the last-observation-carried-forward
analysis (LOCF) uses the last recorded data for all
patients including those exiting treatment.
Significance of seizure-frequency change after
VNS implantation was assessed using the Wilcoxon
signed-rank test. Tests were two-tailed with a sig-
nificance level of 0.05. Seizure reductions of 50, 75
and 90% were calculated based on total seizure
burden (Tables 1 and 2). Analysis was done with
SAS 9.1 (SAS Institute, Cary, NC) and graphics were
produced with R 1.8.0.Results
Total number of VNS-related surgeries in adult and
pediatric patients during the period between 12/
16/1997 and 12/31/2003 was 190. The total numberof left VNS implantations during the same period
was 157; the remaining 33 VNS-related surgeries
aimed to replace the battery and/or stimulator
(19) or remove the device (13 patients). One patient
returned to the operating room for wound debride-
ment without removal of the stimulator.
We identified a total of 49 patients younger than
18 years among the 157 patients with intractable
epilepsy, who underwent implantation of the device
during the specified period. These patients did not
qualify for resective epilepsy surgery or had failed
previous surgical resection. Complete pre- and post-
operative data were available for 46 of the 49
implanted pediatric patients.
Three patients (one preadolescent, age 10.8
years, and two adolescent children, ages 13.1
and 14.6 years at VNS implantation) were excluded
from the analysis, because of brief or no post-
implantation follow-up data. All 3 patients were
out of state and had undergone a comprehensive
presurgical evaluation at our institution prior to
VNS implantation.
Median age at implantation was 12.1 years (range
2.3—17.9, S.D. = 4.3). Median age at onset of epi-
lepsy was 1.5 years (ranging from 2 months to 13.5
years of age, S.D. = 3.4) and median duration of
epilepsy (at the time of implantation) was 8.0 years
(ranging from 1.9 to 16.9 years, S.D. = 3.9). Twenty-
one patients (45.6%) — 10 girls and 11 boys — were
under 12 years of age at the time of surgery
(Table 1). The remaining 25 patients — 11 girls
and 14 boys — had the device implanted between
the ages of 12 and 18 years (Table 2). As expected
there was a statistically significant difference in
duration of epilepsy when comparing the two age
groups (Wilcoxon rank-sum test, p = 0.05). Themed-
ian duration of epilepsy was 6.04 years (S.D. = 2.7)
in the pre-adolescent group (children <12 years at
the time of VNS implantation); the corresponding
value was significantly longer in the adolescent
group: 11.25 years (S.D. = 3.4 years).
Although pre-adolescent children appeared to
have an overall higher seizure burden at baseline
(median seizure-frequency = 290 seizures/month)
therewas also a higher variability in seizure-frequen-
cies observed in the younger group (S.D. = 2434.3). In
the adolescent group median seizure-frequency was
62 seizures/month (S.D. = 1209.1). The difference in
overall seizure-frequency was not statistically signif-
icant (Wilcoxon rank-sum test). Furthermore, there
was no statistically significant difference (Wilcoxon
rank-sum test) in the number of AEDs at the time of
implantation (on average 2 AEDs, ranging from 1 to 3
in the younger and 1—4 in the older group) or the
number of failed AEDs prior to VNS therapy (which
ranged from 4 to 12 AEDs in either group).
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Figure 1 Median percent decrease in seizures from baseline with 95% confidence interval. Longitudinal plot showing
the median percent decrease in seizures at 3, 6, 12, 24 and 36 months as compared to pre-implantation baseline with 95%
confidence intervals (declining number analysis). The continuous black line shows the trend for reduction in seizure-
frequency in this series of pediatric patients (irrespective of age at the time of VNS implantation).The gray lines
correspond to the two different age groups of patients: adolescent children (continuous gray line for patients 12—18 years
of age) and preadolescent children (dashed gray line for children younger than 12 years of age at the time of VNS
implantation).A known etiology of the epilepsy was identified in
15 patients: tuberous sclerosis in 3 (6.5%) and other
malformations of cortical development in 6 (13%);
encephalitis and mitochondrial disorder (two each);
hypothalamic hamartoma and head trauma (one
each). Four patients (8.7%) carried the diagnosis
of idiopathic intractable generalized epilepsy. The
etiology remained unknown in the majority of
patients (58.7%).
Electroencephalography with routine and pro-
longed video-EEG evaluations showed evidence for
a focal or multifocal epilepsy in 19 patients (41.3%).
The remaining 27 patients presented with a general-
ized epilepsy syndrome. Seizure types included gen-
eralized tonic—clonic and other generalized
seizures (myoclonic, absence, and atonic seizures)
and/or complex partial and focal motor seizures
(Tables 1 and 2).
Comorbidities in our patient population included
mental retardation in 33 (71.7%), attention deficit
hyperactivity disorder in 8 (17.4%), and presence of
hemiparesis or quadriparesis in 4 (8.7%). Other less
frequent comorbid conditions included learning dis-
abilities, behavioral dyscontrol, depression, autistic
spectrum disorders, oromotor apraxia, and non-epi-
leptic seizures. Four patients (8.7%) had no identifi-
able comorbidities.
MRI findings consisted ofmalformations of cortical
development in six (including focal cortical dysplasia,
polymicrogyria, macrogyria and lissencephaly), cor-
tical tubers and findings consistent with TuberousSclerosis Complex in three (6.5%), mild cortical atro-
phy in four (8.7%), and dysmorphic mesial temporal
structures in three (7.4%). Other less common find-
ings included bifrontal encephalomalacia, multiple
cortical infarcts, and hypothalamic hamartoma. No
structural abnormalities were evident on MRI in half
of the patients (23/46).
Follow-up intervals extended to 12 months in 39/
46, 24 months in 23, 36 months in 16 and exceeded
48 months in 9/46 patients. Median follow-up was 2
years post-implantation. Fig. 1 shows the median
percent decrease in seizures as compared to base-
line with 95% confidence intervals (declining num-
bers analysis). Fig. 2 summarizes the results
presented in the previous figure (observed values
based on declining numbers) and contrasts them to
those obtained from a different analysis, which is
based on the last-observation-carried-forward
(LOCF).
As compared to baseline, median seizure-fre-
quency reduction in the setting of declining numbers
was 56% at 3 months (n = 46), 50% at 6 months
(n = 45), 63% at 12months (n = 39), 83% at 24months
(n = 23) and 74% at 36 months (n = 16). When the last
observation carried forward analysis was employed
median seizure-frequency reduction in the range of
60% was observed at 1, 2 and 3 years post-VNS.
Specifically, the corresponding LOCF estimates of
median seizure-frequency reduction were: 56% at 3
months, 50% at 6 months, 60% at 12 and at 24
months, and 59% at 36 months (Fig. 2).
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Figure 2 Median percent decrease in seizures from baseline–—observed vs. LOCF. Bar graph showing median percent
decrease in seizures at 3, 6, 12, 24 and 36 months as compared to pre-implantation baseline. Black bars depict values
obtained based on the ‘‘declining number’’ analysis (and correspond to the continuous black line, see Fig. 1). Gray bars
illustrate the results of the ‘‘last observation carried forward’’ (LOCF) analysis (see text).Twenty-seven patients (58.7%) had>50% seizure-
frequency reduction, and out of these 27 respon-
ders, 20 had >75% overall seizure-frequency reduc-
tion by their last follow-up (20/46 or 43.5% of the
entire pediatric group). No response (increase or
<50% reduction) was observed in 19/46 (41.3%).
There was no difference in the number of AEDs used
before and after VNS (Wilcoxon rank-sum test,
p = 0.05) neither in the entire cohort of 46 children
nor in the two subgroups of adolescent and prea-
dolescent children. Both adolescent and pre-ado-
lescent children benefited from VNS implantation.
However, younger patients (implanted before the
age of 12 years) appeared to respond even better to
VNS, when compared to the older group of pediatric
patients (Fig. 1). Statistical comparison of median
reduction in overall seizure-frequencies favored the
preadolescent group at 12 and 24 months of follow-
up (Wilcoxon rank-sum, p = 0.05). A trend towards a
better response was present at 36 and 48 months
despite the decrease in sample size. The difference
in VNS response was not significant early on (at the 3
and 6 month intervals). At their last follow-up visit
none of the 25 adolescents were free of seizures.
However, five pre-adolescent children had been
seizure-free for a period of at least 6 months, when
assessed at their last follow-up visit (Tables 1 and 2).
Similar VNS stimulation parameters were used in
both adolescent and preadolescent children. In this
series pulse width was set at 250 ms and stimulus
frequency at 30 Hz in all patients. The two com-
monly modified parameters, output current and on/off-time (‘‘duty cycle’’), served to subdivide our
patients to the following groups, as proposed by
Labar.13 First, based on the intensity of output
current we identified three groups of patients:
low (L) = 0.25—1 mA, medium (M) = 1.25—2 mA,
and high (H) 2.25 mA, and second based on the
duration of the stimulus (‘‘duty cycle’’) we consid-
ered two groups: ‘‘standard’’ (Std) cycling was
defined as off-times 3 min, and ‘‘rapid’’ (Rpd)
cycling as off-times 1.8 min.
At the end of follow-up the vast majority of
patients were receiving standard cycling. ‘‘Rapid’’
cycling was tried without success in three adoles-
cent (3 out of 25) and three preadolescent (3 out of
21) children, who had failed ‘‘standard’’ VNS
cycling. In the adolescent group standard cycling
was administered to 15 patients using medium cur-
rent intensity (Std-M), to 5 using low (Std-L) and to 2
patients using high current intensity (Std-H). In the
preadolescent children receiving standard cycling
the corresponding numbers were Std-M = 12, Std-
L = 5 children, and Std-H = 1 child. There were no
significant differences between the preadolescent
and adolescent group with respect to these stimula-
tion parameters.
Among this cohort six patients required replace-
ment of the generator’s battery within 2.5—4 years
after initial implantation (Tables 1 and 2). Further-
more, a total of five patients developed a wound
infection around the device (within 1 week to 6
months after implantation). Conservative treatment
with intravenous antibiotics was effective in one
500 A.V. Alexopoulos et al.patient with post-operative wound infection
(Table 2). The rate of deep infections necessitating
device removal in this series of pediatric patientswas
7.7% (4 of 46 patients who had undergone 52 implan-
tation or battery/generator replacement proce-
dures). Only one out of these 4 explanted
generators was subsequently replaced (1 year
later–—Table 1).
Another six stimulators were turned off within 1—
3.5 years after implantation because of the absence
of clinical benefit; three of these were eventually
removed (Tables 1 and 2). In addition, one family
elected not to replace the generator at the end of its
battery’s service. Finally, one patient insisted on
using the device exclusively on-demand (he stated
that magnet activation during seizures decreased
their duration and severity). This data combined
brings the VNS discontinuation rate in our series
to 21.7% (10/46 patients). It should be noted that
three patients in this series died during the period of
observation: two died of probable SUDEP, the other
died following surgery unrelated to VNS.
Several patients (56.5%) experienced stimula-
tion-induced symptoms (throat pain, hoarseness,
cough, drooling) that did not require device
removal. These symptoms were usually mild and
transient, and only limited changes of the genera-
tor’s stimulation settings in 3/46 patients (6.5%).
There were no cases of lead fracture.Discussion
In this retrospective study seizure-frequency out-
comes following VNS implantation and reasons for
VNS discontinuation in children with generalized
and focal pharmacoresistant epilepsy were
assessed. VNS was well-tolerated and effective. In
line with previous open-label and uncontrolled stu-
dies the observed decrease in seizure-frequency in
our pediatric population improved over the first year
of chronic VNS.14 Furthermore, long-term efficacy
was sustained beyond the first 1—2 years of therapy.
Our results in pediatric patients are in agreement
with previous studies demonstrating efficacy in chil-
dren. However, a more favorable response to
chronic VNS in children younger than 12 years as
compared to adolescents (12 years or older) has not
been reported in large pediatric series.3,15—17 In
general, there are fewer publications of the effec-
tiveness of VNS in children as compared to adults
with pharmacoresistant epilepsy,11 andmost reports
of pediatric VNS, similar to our series, have included
a heterogeneous population with both focal and
generalized seizure disorders and variable periods
of follow-up.The first large VNS pediatric epilepsy series was
reported in 1999 and described the results of at least
3 months of VNS treatment in 60 patients (<18 years
of age) enrolled in three different multicenter
trials. In the setting of declining numbers a median
reduction in seizure-frequency of 23% at 3 months,
31% at 6, 34% at 12 and 42% at 18 months was
observed. This study included 16 children younger
than 12 years of age, enrolled in a compassionate
use uncontrolled pre-approval trial. Although these
younger children had more severe seizures than the
older ones they appeared to derive a benefit similar
to that of the entire group.3
More recently 6 centers participated in a large
retrospective series of 125 pediatric patients (<18
years of age) who had been treated with VNS for a
limited period ranging from 3 months to 1 year.
Average seizure reduction was 36.1% at 3 months
and 44.7% at 6 months. The authors did not observe
any difference in seizure reduction among the group
of 41 patients younger than 12 years at the time of
VNS implantation.16
Retrospective results collected from a single cen-
ter were presented by Patwardhan et al. (University
of Alabama) in 2000, and Murphy et al. (University of
Missouri) in 2003. The first study17 examined sei-
zure-frequency and quality of life outcomes in 38
consecutive pediatric patients. At a median follow-
up period of 12 months seizure reduction greater
than 50% was achieved in 26/38 patients (68%).
There was no difference in the response observed
in the younger (<12 years at implantation, n = 28) as
compared to the older pediatric patients.
The second study15 examined the outcome in the
first 100 patients implanted at a single pediatric
epilepsy center; 28 patients in this group had parti-
cipated in the pre-approval VNS trials. Twelve
patients were older than 18 years at the time of
implantation. At a mean follow-up period of 2.7
years seizure reduction greater than 50% was
achieved in 45% of patients. Of note 18% of patients
in this series were seizure-free for 6 months at their
last follow-up. The authors reported similar percen-
tages of seizure-frequency reduction in younger (6—
11 years of age; n = 50) and older patients (12—18
years of age at the time of VNS implantation;
n = 34).
The reason our pre-adolescent children had
greater seizure reductions compared with published
reports is not clear. The two age groups did not differ
in terms of overall seizure-frequency, VNS stimula-
tion parameters, number of failed AEDs, number of
AEDs at the time of VNS implantation, or number of
AEDs during the period of chronic VNS. All children in
this serieswere followed closely for at least 6months
after VNS implantation. There was no difference
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adjustment, and as expected, pre-adolescent chil-
dren had a shorter duration of epilepsy.
The apparent greater efficacy of VNS in this group
may implicate mechanisms related to brain plasti-
city and/or earlier use of the device.18 However, it
should be emphasized that these observations are
uncontrolled and that the influence of maturation or
other extraneous effects cannot be excluded.
Another variable is the frequency of stimulator
adjustments following implantation. Patients in this
series were followed closely and at regular intervals
post-VNS implantation. It is possible that this entire
cohort of pediatric patients underwent more fre-
quent and more regular VNS adjustments as com-
pared to VNS adjustments reported in other studies.
Other investigators have suggested that children
with highly medication-resistant seizures, such as
children with Lennox-Gastaut in particular, may
derive significant benefit from VNS.10,19,20
VNS is usually not associated with the common
central nervous system adverse effects that some-
times limit use of AEDs (such as dizziness, ataxia,
insomnia, cognitive impairment, weight gain or sex-
ual dysfunction). Moreover most patients become
accustomed to stimulation-related side effects,
which tend to diminish over time. In our study
VNS-related adverse effects weremild and transient
and only limited changes of the generator’s stimula-
tion settings in three patients.
Complications associated with implantation
have included infection at the incision, lead frac-
tures and transient paralysis of the left vocal
cord.21,22 The VNS discontinuation rate in our series
was 21.7% (10/46 patients) and primarily reflected
the absence of clinical response after 12 months or
more of intermittent VNS. Five of our patients
developed a wound infection around the generator,
which necessitated device removal in four. Inci-
sional infection was present in the immediate
post-operative period in 3/5 patients. The other
two, who were not compliant with instructions for
proper wound care, developed signs of infection 3—
6 months after surgery (Tables 1 and 2). The overall
rate of deep infections necessitating device
removal in this series of pediatric patients was
7.7% (4/52 patients who had undergone implanta-
tion or battery/generator replacement proce-
dures). Such infections requiring explantation
may be more common in younger age children,
especially those with mental retardation.23 Fre-
quent drooling resulting to saliva/food soiling of
the incision, and/or picking at the incision and
inadvertent wound manipulation are not uncom-
mon occurrences in this population and may
account for the higher infection rate. In this seriessevere developmental delay was present in three of
the four patients, who had the device removed
because of infection.
This study has inherent limitations because of
its retrospective, uncontrolled nature (class IV).24
Furthermore, patient assessment in this series was
not blinded and seizure-frequency data was based
on reporting by patients and/or families. Indeed,
the post-approval VNS literature suffers from the
lack of randomized controlled trials examining
longer-term outcomes. Evidence-based decisions
in both adult and pediatric VNS candidates remain
complicated, in part due to the narrow scope of
the initial randomized control studies of VNS
(which were limited to patients aged 13—60 years,
who had drug-resistant focal epilepsy, and only
examined the median seizure-frequency reduction
over a 3-month treatment period).25
This limited evidence from randomized trials
should be complemented by long-term studies that
reflect everyday clinical practice. Non-randomized
longer-term studies (>6 months) suggest that the
effect of VNS may improve with time.7,26 At this
time, however the weight of evidence that supports
the use of VNS in pre-adolescent children is weak,27
despite promising results from studies similar to
ours. We agree with previous investigators who
prompt us to interpret these results with caution
‘‘because of the uncontrolled, open-label design,
enrollment of patients who have a variety of epi-
lepsy syndromes; differing lengths of follow-up, and
the varied and changeable antiepileptic medica-
tions coadministered’’.14 Finally, we cannot spec-
ulate on the net benefit of intermittent VNS without
a non-stimulated control group.
Quality of life (QOL) indicators were not exam-
ined in this study. The VNS outcome registry main-
tained by the manufacturer captures open-label
clinical data including seizure control and QOL para-
meters (alertness, verbal communication, memory,
school/professional achievement, mood, postictal
state, and seizure clustering), which are collected
by physicians on a voluntary basis. Despite the
integral biases in selection, assessment and report-
ing of subjects enrolled in the registry, this data
suggest that chronic VNS may lead to improvement
in QOL domains.28
A few pediatric VNS series indicate that VNS
improves QOL in treated children. Of note, it has
been suggested that improvement in quality of life
(QOL) may be independent from the antiseizure
effect of VNS. In a series of 16 Lennox Gastaut
patients the best improvement in QOL was seen in
patients,whodid not benefit from theVNS in terms of
seizure-frequency reduction.29 In another series of
patients with autism and Landau-Kleffner syndrome
502 A.V. Alexopoulos et al.improvements in QOL were seen in up to 76% of
pediatric patients at 12months of follow-up.30 These
studies utilize variable QOL assessment tools and
have limitations inherent to their open-label add-
on designs.17,31
Chronic vagus nerve stimulation shows promise,
when used as adjunctive therapy in children with
medically intractable (focal and/or generalized)
epilepsy. Because of its non-pharmacologic nature
this therapy is devoid of the frequent adverse and
interactive effects encountered with AED polyphar-
macy in the vulnerable pediatric population. We
conclude that the use of VNS in children merits
further investigation in a randomized controlled
fashion, but at the same time the limited available
evidence supports its continued use in pre-adoles-
cent and adolescent children. Future research using
economic decision analysis could help determine
whether the potential benefits are worth the addi-
tional cost (removal of infected generator, need for
battery changes) in a pediatric population. In the
meantime, empiric evidence similar to ours suggests
that chronic VNS should be considered for the treat-
ment of children younger than 12 years of age,
as they appear to respond as well or even better
than adolescent children with pharmacoresistant
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